DISRUPT PAD III Observational Study

NCT ID: NCT05881421

Last Updated: 2023-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1373 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-16

Study Completion Date

2021-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Disrupt PAD III study was designed as a randomized controlled trial (RCT) with an additional observational registry component. The registry, referred to as the Disrupt PAD III Observational Study (PAD III OS), was a global, prospective, multi-center, single-arm registry of the Shockwave Peripheral Intravascular Lithotripsy (IVL) System. The objective of this study was to assess the real-world acute performance of IVL in the treatment of calcified, stenotic, peripheral arteries that may not qualify for inclusion in the RCT. The study was designed to enroll a maximum of 1500 subjects from up to 60 global sites with a minimum of 200 subjects treated with the S4 IVL catheter, a line extension designed to treat smaller diameter peripheral vessels, including calcified below-the-knee (BTK) lesions.

Subjects were required to have target lesions in the iliac, femoral, ilio-femoral, popliteal, or infra-popliteal arteries with at least moderate calcification as determined by the investigator, defined as calcification within the lesion on both sides of the vessel assessed by angiography. Adjunctive therapies such as atherectomy, specialty balloons, and stents were allowed. Subjects were followed through discharge.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects intended to be treated with Shockwave Medical Lithoplasty for de-novo or restenotic lesions of the femoral, ilio-femoral, popliteal, and infra-popliteal arteries.
2. Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limb.
3. Age of subject is \> 18.
4. Subject of subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
5. Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length.

Exclusion Criteria

1. Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Lithoplasty as per Instructions for Use (IFU) or investigator's opinion.
2. Subject already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shockwave Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford Hospital

Palo Alto, California, United States

Site Status

Rocky Mountain Regional VA Medical Center

Aurora, Colorado, United States

Site Status

UCHealth Northern Colorado

Loveland, Colorado, United States

Site Status

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Tallahassee Research Institute Inc.

Tallahassee, Florida, United States

Site Status

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Site Status

Alexian Brothers Medical Center

Elk Grove Village, Illinois, United States

Site Status

Midwest Cardiovascular Research Foundation

Davenport, Iowa, United States

Site Status

Steward St. Elizabeth's Medical Center

Brighton, Massachusetts, United States

Site Status

St. Joseph Mercy Oakland

Pontiac, Michigan, United States

Site Status

North Mississippi Medical Center

Tupelo, Mississippi, United States

Site Status

St. Luke's Cardiovascular Consultants

Kansas City, Missouri, United States

Site Status

Mount Sinai West

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

NC Heart & Vascular Research, LLC

Raleigh, North Carolina, United States

Site Status

Ohio Health Research Institute

Columbus, Ohio, United States

Site Status

St. John Clinic

Bartlesville, Oklahoma, United States

Site Status

Providence Heart & Vascular Institute

Portland, Oregon, United States

Site Status

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, United States

Site Status

Pinnacle Health Cardiovascular Institute

Harrisburg, Pennsylvania, United States

Site Status

The Miriam Hospital

Providence, Rhode Island, United States

Site Status

Baptist Medical Center

Memphis, Tennessee, United States

Site Status

St. David's Heart and Vascular (Austin Heart)

Austin, Texas, United States

Site Status

Baylor Clinic McNair Campus

Houston, Texas, United States

Site Status

Charleston Area Medical Center

Charleston, West Virginia, United States

Site Status

Evangelisches Krankenhaus Mulheim an der Ruhr

Mülheim, , Germany

Site Status

St. Franziskus Hospital

Münster, , Germany

Site Status

RoMed Klinikum Rosenheim

Rosenheim, , Germany

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany New Zealand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP 60892 OS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The PERSEVERE Study
NCT06588634 RECRUITING NA
The PEERLESS Study
NCT05111613 COMPLETED NA
The PEERLESS II Study
NCT06055920 RECRUITING NA